Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy

Blood

Volumn 96, Issue 9, 2000, Pages 2943-2950

  Hideshima, T ^a   Chauhan, D ^a   Shima, Y ^a   Raje, N ^a   Davies, F E ^a   Tai, Y T ^a   Treon, S P ^a   Lin, B ^a   Schlossman, R L ^a   Richardson, P ^a   Muller, G ^a   Stirling, D I ^a   Anderson, K C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; IMMUNOMODULATING AGENT; INTERLEUKIN 6; MELPHALAN; PROTEIN TYROSINE KINASE; THALIDOMIDE; THALIDOMIDE DERIVATIVE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 0034331194     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.9.2943     Document Type: Article

References (31)

1. Thalidomide on the comeback trail
2. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
3. Thalidomide: Therapeutic potential in hematologic malignancies
4. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma
5. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma
6. Thalidomide is an inhibitor of angiogenesis
7. Anti-tumor activity of thalidomide in refractory multiple myeloma
8. Thalidomide: A revival story
9. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
10. Adhesion of human myelomaderived cell lines to bone marrow stromal cells stimulates IL-6 secretion
11. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB
12. Multiple myeloma: Increasing evidence for a multistep transformation process
13. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
14. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade
15. Differential cytokine modulation and T Cell activation by two distinct classes of thalidomide analogs that are potent inhibitors of TNF-α
16. Expression of vascular endothelial growth factor and its receptor in hematological malignancies
17. + subset
18. Isolation and characterization of human multiple myeloma cell enriched populations
19. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade
20. Interleukin-6 overcomes p21(WAF1) upregulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells
21. Characterization of signaling cascades by human interleukin-6 versus Kaposi's sarcoma-associated herpesvirus encoded viral interleukin-6
22. RAFTK/PYK2-dependent and independent apoptosis in multiple myeloma cells
23. Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism
24. Blockade of mitogen-activated protein kinase cascade signaling in interleukin-6 independent multiple myeloma cells
25. Interleukin-6 inhibits Fas-induced apoptosis ano stress-activated protein kinase activation in multiple myeloma cells
26. Response of purified myeloma cells to hematopoietic growth factors
27. CD40 ligand triggered interleukin-6 secretion in multiple myeloma
28. Increased level of p21(WAF1.CIP1) in human brain tumors
29. Genetic determinants of p53-induced apoptosis and growth arrest
30. Resistance to apoptosis conferred by Cdk inhibitors during myocyte differentiation
31. Cytochrome-c dependent independent induction of apoptosis in multiple myeloma cells